Egetis Therapeutics Financials
| EGTX Stock | SEK 5.60 0.04 0.71% |
Egetis |
Understanding current and past Egetis Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Egetis Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Egetis Therapeutics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Egetis Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Egetis Therapeutics AB. Check Egetis Therapeutics' Beneish M Score to see the likelihood of Egetis Therapeutics' management manipulating its earnings.
Egetis Therapeutics Stock Summary
Egetis Therapeutics competes with Hansa Biopharma, Xbrane Biopharma, and BioArctic. Egetis Therapeutics AB , a pharmaceutical drug development company, focuses on projects in late-stage development for the treatment of serious rareniche diseases with unmet medical needs in the orphan drug segment. Egetis Therapeutics AB was founded in 2006 and is based in Stockholm, Sweden. Egetis Therapeutics operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 11 people.| Instrument | Sweden Stock View All |
| Exchange | Stockholm Exchange |
| ISIN | SE0003815604 |
| Business Address | Klara Norra Kyrkogata |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | Dow Jones Industrial |
| Website | www.egetis.com |
| Phone | 46 86 79 72 10 |
| Currency | SEK - Swedish Kronor |
You should never invest in Egetis Therapeutics without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Egetis Stock, because this is throwing your money away. Analyzing the key information contained in Egetis Therapeutics' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Egetis Therapeutics Key Financial Ratios
Egetis Therapeutics' financial ratios allow both analysts and investors to convert raw data from Egetis Therapeutics' financial statements into concise, actionable information that can be used to evaluate the performance of Egetis Therapeutics over time and compare it to other companies across industries.Egetis Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Egetis Therapeutics's current stock value. Our valuation model uses many indicators to compare Egetis Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Egetis Therapeutics competition to find correlations between indicators driving Egetis Therapeutics's intrinsic value. More Info.Egetis Therapeutics AB is rated # 2 in return on equity category among its peers. It also is rated # 2 in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Egetis Therapeutics' earnings, one of the primary drivers of an investment's value.Egetis Therapeutics Systematic Risk
Egetis Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Egetis Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was four with a total number of output elements of fifty-seven. The Beta measures systematic risk based on how returns on Egetis Therapeutics correlated with the market. If Beta is less than 0 Egetis Therapeutics generally moves in the opposite direction as compared to the market. If Egetis Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Egetis Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Egetis Therapeutics is generally in the same direction as the market. If Beta > 1 Egetis Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Egetis Therapeutics November 27, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Egetis Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Egetis Therapeutics AB. We use our internally-developed statistical techniques to arrive at the intrinsic value of Egetis Therapeutics AB based on widely used predictive technical indicators. In general, we focus on analyzing Egetis Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Egetis Therapeutics's daily price indicators and compare them against related drivers.
| Downside Deviation | 3.28 | |||
| Information Ratio | (0.03) | |||
| Maximum Drawdown | 28.58 | |||
| Value At Risk | (5.00) | |||
| Potential Upside | 6.76 |
Additional Tools for Egetis Stock Analysis
When running Egetis Therapeutics' price analysis, check to measure Egetis Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Egetis Therapeutics is operating at the current time. Most of Egetis Therapeutics' value examination focuses on studying past and present price action to predict the probability of Egetis Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Egetis Therapeutics' price. Additionally, you may evaluate how the addition of Egetis Therapeutics to your portfolios can decrease your overall portfolio volatility.